TY - JOUR
T1 - Migraine
T2 - disease characterisation, biomarkers, and precision medicine
AU - Ashina, Messoud
AU - Terwindt, Gisela M.
AU - Al-Karagholi, Mohammad Al Mahdi
AU - de Boer, Irene
AU - Lee, Mi Ji
AU - Hay, Debbie L.
AU - Schulte, Laura H.
AU - Hadjikhani, Nouchine
AU - Sinclair, Alexandra J.
AU - Ashina, Håkan
AU - Schwedt, Todd J.
AU - Goadsby, Peter J.
N1 - Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/4/17
Y1 - 2021/4/17
N2 - Migraine is a disabling neurological disorder, diagnosis of which is based on clinical criteria. A shortcoming of these criteria is that they do not fully capture the heterogeneity of migraine, including the underlying genetic and neurobiological factors. This complexity has generated momentum for biomarker research to improve disease characterisation and identify novel drug targets. In this Series paper, we present the progress that has been made in the search for biomarkers of migraine within genetics, provocation modelling, biochemistry, and neuroimaging research. Additionally, we outline challenges and future directions for each biomarker modality. We also discuss the advances made in combining and integrating data from multiple biomarker modalities. These efforts contribute to developing precision medicine that can be applied to future patients with migraine.
AB - Migraine is a disabling neurological disorder, diagnosis of which is based on clinical criteria. A shortcoming of these criteria is that they do not fully capture the heterogeneity of migraine, including the underlying genetic and neurobiological factors. This complexity has generated momentum for biomarker research to improve disease characterisation and identify novel drug targets. In this Series paper, we present the progress that has been made in the search for biomarkers of migraine within genetics, provocation modelling, biochemistry, and neuroimaging research. Additionally, we outline challenges and future directions for each biomarker modality. We also discuss the advances made in combining and integrating data from multiple biomarker modalities. These efforts contribute to developing precision medicine that can be applied to future patients with migraine.
UR - http://www.scopus.com/inward/record.url?scp=85103935054&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103935054&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(20)32162-0
DO - 10.1016/S0140-6736(20)32162-0
M3 - Review article
C2 - 33773610
AN - SCOPUS:85103935054
SN - 0140-6736
VL - 397
SP - 1496
EP - 1504
JO - The Lancet
JF - The Lancet
IS - 10283
ER -